Article
Bisphosphonate label revised to include dental exam recommendation
Novartis and the FDA have revised the prescribing information of zoledronic acid (Zometa) to include the occurrence of osteonecrosis of the jaw.
Novartis and the FDA have revised the prescribing information of zoledronic acid (Zometa) to include the occurrence of osteonecrosis of the jaw. The updated information recommends that cancer patients receive a dental examination prior to initiating therapy with IV bisphosphonates and avoid invasive dental procedures while receiving bisphosphonate treatment.
For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition, the FDA said.
Related Videos
Urology CNP discusses sensitivity in communication, physical exam
Ekene Enemchukwu, MD, on the need for better education on GSM, vaginal estrogen
Urologist discusses drug cost savings, price transparency
Ekene Enemchukwu, MD, on underutilization of vaginal estrogen for GSM
Ekene Enemchukwu, MD, on trends in vaginal estrogen use for GSM
Raymond Xu, MD, discusses Cost Plus Drugs and urogynecologic medications
Ekene Enemchukwu, MD, on vaginal estrogen for genitourinary syndrome of menopause
Why a personalized approach is key to prolapse and OAB management
Anna Myers, CNP, on the overlap between urological and gynecological conditions
Sarah Ponce discusses pelvic and vulvovaginal pain among medical trainees
Related Content
